Sanofi and GSK report successful efficacy results against Omicron
COVID-19 Beta-containing vaccine provides 75.1% efficacy in participants previously infected with coronavirus
24th June 2022
Latest news
Positive MHRA decision for Briviact
MHRA extends UCB’s therapy for the treatment of partial-onset seizures
24th June 2022
Pharma poised but no recorded monkeypox deaths
Global surveillance systems show that recorded cases do not include any deaths
23rd June 2022
Novartis invests $250m in malaria elimination commitment
The company has renewed its pledge to eliminate neglected tropical diseases and malaria over five years
23rd June 2022
Novartis lung cancer drug Tabrecta gets approval
Novartis receives approval from the European Commission for Tabrecta for the treatment of non-small cell lung cancer
22nd June 2022
NICE opts to reject Acorda’s MS drug Fampyra
The MS Society responds as MS therapy Fampyra is rejected
22nd June 2022
AstraZeneca’s Eplontersen meets endpoints in critical phase 3 trial
Eplontersen significantly improved patient-reported quality of life following successful research
21st June 2022
University of Strathclyde develops 3D breast cancer screening tool
Pre-clinical screening technology could increase cancer test numbers by 50 times
21st June 2022
RMI’s COVID-19 vaccine partnership with Acacium proves a success
The joint aim of the companies was to provide vaccines to vulnerable communities
20th June 2022
Blood vessel breakthrough is major step towards Alzheimer’s treatment
The discovery may lead to development of drugs that halt disease progression and stop memory loss
20th June 2022
Novartis receives vital licence for Scemblix
Therapy represents the first STAMP inhibitor for patients with chronic myeloid leukaemia
17th June 2022
NICE recommends Eli Lilly’s breast cancer therapy
Verzenios in combination with endocrine treats people with early breast cancer who are at high-risk of recurrence
17th June 2022
Genedrive genetic variant test for infants evaluated by NICE
The MT-RNR1 test was assessed under NICE’s diagnostics assessment programme
16th June 2022
Nordic Bioscience and Roche strengthen collaboration
The companies will focus on the development of biomarkers for chronic diseases
16th June 2022
Keensight Capital invests in AstraZeneca spin-out
The deal will boost CatSci’s ability to deliver best-in-class medicines to patients worldwide
15th June 2022
